Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Pancreatic Ductal Adenocarcinoma Clinical Trials

8 recruiting trials for Pancreatic Ductal Adenocarcinoma. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
8
Total Trials
8
Recruiting Now
0
Phase 3 Trials
8
Sponsors

Recruiting Trials

RECRUITINGPhase 1 / Phase 2NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation...

Sponsor: Perspective TherapeuticsEnrolling: 1123 locations
RECRUITINGPhase 1 / Phase 2NCT05482893

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced...

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics,...

Sponsor: Phanes TherapeuticsEnrolling: 25811 locations
RECRUITINGPhase 1 / Phase 2NCT07284277

TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

The purpose of this clinical trial is to assess the safety and tolerability of TTFields in combination with chemotherapy in adults with metastatic pancreatic adenocarcinoma based...

Sponsor: Clinica Universidad de Navarra, Universidad de NavarraEnrolling: 305 locations
RECRUITINGPhase 2NCT06015724

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and...

The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax...

Sponsor: Georgetown UniversityEnrolling: 542 locations
RECRUITINGPhase 1NCT07024615

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 253 locations
RECRUITINGPhase 1NCT05257993

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or...

The purpose of this study is to assess the safety, tolerability of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in...

Sponsor: Onconic Therapeutics Inc.Enrolling: 304 locations
RECRUITINGPhase 2NCT06503146

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET...

Sponsor: National Cancer Institute (NCI)Enrolling: 3201 location
RECRUITINGNCT06275737

POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer

This is a multicenter, two-cohort, open-label, single-arm feasibility study. The primary objective is to assess the feasibility of the 8-week trimodal prehabilitation program...

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative GroupEnrolling: 724 locations